Next earnings date: 27 Oct 2025

Enzo Biochem, Inc. – NYSE:ENZ
Enzo Biochem stock price today
Enzo Biochem stock price monthly change
Enzo Biochem stock price quarterly change
Enzo Biochem stock price yearly change
Enzo Biochem key metrics
Market Cap | 40.30M |
Enterprise value | N/A |
P/E | -1.66 |
EV/Sales | -0.21 |
EV/EBITDA | 0.96 |
Price/Sales | 1.25 |
Price/Book | 0.79 |
PEG ratio | -0.26 |
EPS | -0.16 |
Revenue | 13.02M |
EBITDA | 3.71M |
Income | 36.62M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -75.34% |
Oper. margin | -28.08% |
Gross margin | 45.22% |
EBIT margin | -28.08% |
EBITDA margin | 28.55% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEnzo Biochem stock price history
Enzo Biochem stock forecast
Enzo Biochem financial statements
Apr 2023 | 16.10M | -14.72M | -91.44% |
---|---|---|---|
Jul 2023 | -19.66M | 57.43M | -292.12% |
Jan 2024 | 8.55M | -3.06M | -35.79% |
Apr 2024 | 8.02M | -3.02M | -37.65% |
Apr 2023 | 72061000 | 53.13M | 73.73% |
---|---|---|---|
Jul 2023 | 121880000 | 43.41M | 35.62% |
Jan 2024 | 99077000 | 28.30M | 28.57% |
Apr 2024 | 93469000 | 24.43M | 26.15% |
Apr 2023 | -5.05M | -666K | 3.27M |
---|---|---|---|
Jul 2023 | -17.03M | 101.16M | -4.24M |
Jan 2024 | -8.93M | -25K | -22K |
Apr 2024 | -2.86M | -143K | -44K |
Enzo Biochem alternative data
Aug 2023 | 465 |
---|---|
Sep 2023 | 465 |
Oct 2023 | 465 |
Nov 2023 | 465 |
Dec 2023 | 179 |
Jan 2024 | 179 |
Feb 2024 | 179 |
Mar 2024 | 179 |
Apr 2024 | 179 |
Jun 2024 | 179 |
Jul 2024 | 179 |
Enzo Biochem other data
Period | Buy | Sel |
---|---|---|
Jun 2022 | 128500 | 0 |
Jul 2022 | 135000 | 0 |
Nov 2022 | 100000 | 0 |
Dec 2022 | 0 | 1206 |
Jan 2023 | 11800 | 0 |
Feb 2023 | 15000 | 3222 |
Patent |
---|
Application IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNTHETIC PEPTIDE AND TRANSFORMING GROWTH FACTOR BETA Filling date: 12 Oct 2021 Issue date: 27 Jan 2022 |
Application Filling date: 5 Oct 2021 Issue date: 27 Jan 2022 |
Grant Utility: Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta Filling date: 2 Jun 2020 Issue date: 16 Nov 2021 |
Grant Filling date: 29 Apr 2019 Issue date: 9 Nov 2021 |
Application COMPREHENSIVE AND COMPARATIVE FLOW CYTOMETRY-BASED METHODS FOR IDENTIFYING THE STATE OF A BIOLOGICAL SYSTEM Filling date: 4 May 2021 Issue date: 30 Sep 2021 |
Application Filling date: 10 Mar 2021 Issue date: 23 Sep 2021 |
Application Filling date: 10 Mar 2021 Issue date: 23 Sep 2021 |
Grant Filling date: 19 Dec 2018 Issue date: 20 Jul 2021 |
Application Filling date: 29 Mar 2021 Issue date: 15 Jul 2021 |
Application Filling date: 19 Nov 2020 Issue date: 10 Jun 2021 |
Quarter | Transcript |
---|---|
Q1 2023 13 Dec 2022 | Q1 2023 Earnings Call Transcript |
Q3 2022 10 Jun 2022 | Q3 2022 Earnings Call Transcript |
Q2 2022 14 Mar 2022 | Q2 2022 Earnings Call Transcript |
Q1 2022 15 Dec 2021 | Q1 2022 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Elazar Rabbani Ph.D. (1943) Co-Founder, Chairman, Chief Scientific Officer & Sec. | $808,620 |
Mr. Barry W. Weiner (1950) Founder, Treasurer & Pres | $723,520 |
Dr. Dieter Schapfel M.D. (1963) Chief Medical Director of Enzo Clinical Labs | $344,030 |
-
What's the price of Enzo Biochem stock today?
One share of Enzo Biochem stock can currently be purchased for approximately $0.31.
-
When is Enzo Biochem's next earnings date?
Enzo Biochem, Inc. is estimated to report earnings on Monday, 27 Oct 2025.
-
Does Enzo Biochem pay dividends?
Yes, Enzo Biochem pays dividends and its trailing 12-month yield is 13.74% with 0% payout ratio. The last Enzo Biochem stock dividend of $0 was paid on 6 Sep 2025.
-
How much money does Enzo Biochem make?
Enzo Biochem has a market capitalization of 40.30M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.72% to 31.91M US dollars.
-
What is Enzo Biochem's stock symbol?
Enzo Biochem, Inc. is traded on the NYSE under the ticker symbol "ENZ".
-
What is Enzo Biochem's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Enzo Biochem?
Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Enzo Biochem's key executives?
Enzo Biochem's management team includes the following people:
- Dr. Elazar Rabbani Ph.D. Co-Founder, Chairman, Chief Scientific Officer & Sec.(age: 82, pay: $808,620)
- Mr. Barry W. Weiner Founder, Treasurer & Pres(age: 75, pay: $723,520)
- Dr. Dieter Schapfel M.D. Chief Medical Director of Enzo Clinical Labs(age: 62, pay: $344,030)
-
Is Enzo Biochem founder-led company?
Yes, Enzo Biochem is a company led by its founders Dr. Elazar Rabbani Ph.D. and Mr. Barry W. Weiner.
-
How many employees does Enzo Biochem have?
As Jul 2024, Enzo Biochem employs 179 workers.
-
When Enzo Biochem went public?
Enzo Biochem, Inc. is publicly traded company for more then 45 years since IPO on 12 Jun 1980.
-
What is Enzo Biochem's official website?
The official website for Enzo Biochem is enzo.com.
-
Where are Enzo Biochem's headquarters?
Enzo Biochem is headquartered at 527 Madison Avenue, New York, NY.
-
How can i contact Enzo Biochem?
Enzo Biochem's mailing address is 527 Madison Avenue, New York, NY and company can be reached via phone at +212 5830100.
Enzo Biochem company profile:

Enzo Biochem, Inc.
enzo.comNYSE
125
Medical - Diagnostics & Research
Healthcare
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
New York, NY 10022
CIK: 0000316253
ISIN: US2941001024
CUSIP: 294100102